• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.975 +0.025 (+1.28%)
Streaming Delayed Price Updated: 10:15 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,740
Open 1.970
Bid (Size) 1.970 (600)
Ask (Size) 1.980 (700)
Prev. Close 1.950
Today's Range 1.940 - 1.995
52wk Range 0.7100 - 2.616
Shares Outstanding 116,236,018
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow ↗
March 09, 2026
Via Chartmill
News headline image
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 09, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire

Performance

YTD
+44.2%
+44.2%
1 Month
-4.1%
-4.1%
3 Month
+53.1%
+53.1%
6 Month
+46.3%
+46.3%
1 Year
+89.9%
+89.9%

More News

Read More
News headline image
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
March 02, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
February 23, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
February 17, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
Coherus BioSciences's Earnings Outlook ↗
November 05, 2025
Via Benzinga
What's going on in today's pre-market session ↗
February 13, 2026
Via Chartmill
News headline image
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
February 12, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
January 28, 2026
Via Chartmill
What's going on in today's session ↗
January 23, 2026
Via Chartmill
Which stocks are moving on Friday? ↗
January 23, 2026
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
January 23, 2026
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
January 22, 2026
Via Chartmill
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 12, 2026
From Equity Insider
Via GlobeNewswire
News headline image
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
January 05, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
December 08, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
November 07, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
November 06, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
October 23, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
October 10, 2025
Via Benzinga

Frequently Asked Questions

Is Coherus Oncology, Inc. - Common Stock publicly traded?
Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
What exchange does Coherus Oncology, Inc. - Common Stock trade on?
Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
What is the current price of Coherus Oncology, Inc. - Common Stock?
The current price of Coherus Oncology, Inc. - Common Stock is 1.975
When was Coherus Oncology, Inc. - Common Stock last traded?
The last trade of Coherus Oncology, Inc. - Common Stock was at 03/11/26 10:15 AM ET
What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
The market capitalization of Coherus Oncology, Inc. - Common Stock is 229.57M
How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
Coherus Oncology, Inc. - Common Stock has 230M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap